BCL2L11

Across TCGA pan-cancer cohorts, BCL2L11 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BCL2L11 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BCL2L11 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BCL2L11 expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

LUAD, PDAC, and GBM are the cancer types where BCL2L11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	II,III,IV	0.270	0.902	.001	31	view →
PDAC	OS	Median	All	0.221	0.844	.038	12	view →
GBM	DFS	Quartile	All	0.718	0.236	.001	10	view →
UCEC	DFS	Median	All	0.883	1.000	.018	6	view →
OV	DFS	Tertile	All	0.792	1.000	.035	4	view →
CCRCC	OS	Median	III,IV	0.873	0.596	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BCL2L11–LUAD (OS)

Open the LUAD breakdown →